GLP-1 Drugs: Weight Regain After Stopping Semaglutide & Tirzepatide

The increasing use of injectable GLP-1 drugs – medications initially developed for managing type 2 diabetes – has sparked considerable interest, and equally pressing questions, about their long-term effects. A novel analysis from the Cleveland Clinic, published March 12, 2026, offers some reassuring insights into what happens when patients discontinue these medications, semaglutide, and tirzepatide. The study suggests that, on average, stopping these drugs doesn’t necessarily lead to substantial weight regain, largely because many individuals either restart the medication or transition to another obesity treatment.

Understanding GLP-1 Medications and Their Rise

GLP-1, or glucagon-like peptide-1, is a naturally occurring hormone that plays a role in regulating appetite and blood sugar levels. GLP-1 receptor agonists, the class of drugs under scrutiny, mimic the effects of this hormone. Medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have gained widespread attention not only for their effectiveness in managing type 2 diabetes but also for their significant impact on weight loss. The Cleveland Clinic study, and related reporting from Spectrum News 1, addresses a critical gap in our understanding: what happens after patients stop taking these medications.

Study Design and Key Findings

Researchers at the Cleveland Clinic retrospectively analyzed data from nearly 8,000 adults who had discontinued semaglutide or tirzepatide. The patients, located in Ohio and Florida, had been using the injectables for either obesity or type 2 diabetes and stopped the medication within a three-to-12-month period. The analysis revealed that patients treated for obesity lost an average of 8.4% of their body weight before stopping the medication, and regained only an average of 0.5% one year later. Those treated for type 2 diabetes experienced an average weight loss of 4.4% before discontinuation, followed by an additional 1.3% loss one year after stopping. Importantly, 45% of the obesity group and 56% of the diabetes group either continued to lose weight or maintained their weight loss after stopping the medication. National Today provides a concise overview of these findings.

Why Isn’t There Significant Weight Regain?

The study’s lead researcher, Hamlet Gasoyan, from Cleveland Clinic’s Center for Value-Based Care Research, suggests a key reason for the relatively modest weight regain: many patients restart the original medication or switch to another obesity treatment. “Our real‑world data indicate that many patients who stop semaglutide or tirzepatide restart the medication or transition to another obesity treatment, which may explain why they regain less weight than patients in randomized trials,” Gasoyan explained. This finding highlights the importance of ongoing support and management for individuals using these medications. It also suggests that the experience in a real-world clinical setting differs from the more controlled environment of randomized clinical trials, where adherence to discontinuation is often higher.

The Role of Lifestyle Interventions

Beyond simply restarting medication, many patients successfully stabilized their weight through alternative treatments and lifestyle changes. This underscores the importance of a holistic approach to weight management, encompassing dietary modifications, increased physical activity, and behavioral support. Even as the study doesn’t detail the specifics of these interventions, it suggests that they play a crucial role in maintaining weight loss after discontinuing GLP-1 drugs.

Limitations and Considerations

It’s vital to acknowledge the limitations of this study. As a retrospective analysis, it relies on existing data and cannot establish a causal relationship between stopping GLP-1 drugs and weight regain. The study population was limited to patients in Ohio and Florida, which may not be representative of the broader population. The study doesn’t provide detailed information about the reasons why patients discontinued the medication in the first place – factors such as cost, side effects, or lack of access could influence the results. The study also doesn’t account for the duration of GLP-1 use before discontinuation, which could impact long-term outcomes.

What Does This Imply for Patients and Clinicians?

These findings offer a more nuanced understanding of the long-term effects of GLP-1 drugs. They suggest that discontinuing these medications doesn’t automatically lead to significant weight regain, particularly when patients have access to ongoing support and are willing to explore alternative treatment options. However, it’s crucial to remember that individual results may vary. Patients considering stopping GLP-1 drugs should have a thorough discussion with their healthcare provider to develop a personalized plan that addresses their individual needs and circumstances. This plan should include strategies for maintaining weight loss, managing potential side effects, and addressing any underlying health conditions.

Looking Ahead: Ongoing Research and Guidance Updates

The Cleveland Clinic study adds to a growing body of evidence regarding the long-term effects of GLP-1 drugs. Further research is needed to better understand the optimal duration of treatment, the factors that predict successful discontinuation, and the long-term impact on cardiovascular health and other outcomes. Public health organizations, such as the Centers for Disease Control and Prevention (CDC), will likely continue to monitor the use of these medications and update their guidance as new evidence emerges. Clinicians should stay informed about the latest research and recommendations to provide the best possible care for their patients. The evolving landscape of obesity and diabetes treatment necessitates a continuous cycle of research, evaluation, and adaptation.